dc.creator | Cruz Ojeda, Patricia de la | es |
dc.creator | Schmid, Tobias | es |
dc.creator | Boix, Loreto | es |
dc.creator | Moreno, Manuela | es |
dc.creator | Sapena, Víctor | es |
dc.creator | Praena Fernandez, Juan Manuel | es |
dc.creator | Gómez Bravo, Miguel Ángel | es |
dc.creator | Muntané Relat, Jordi | es |
dc.date.accessioned | 2023-04-21T14:31:51Z | |
dc.date.available | 2023-04-21T14:31:51Z | |
dc.date.issued | 2022-08-28 | |
dc.identifier.citation | Cruz Ojeda, P.d.l., Schmid, T., Boix, L., Moreno, M., Sapena, V., Praena Fernandez, J.M.,...,Muntané Relat, J. (2022). miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Cells, 11 (17), 2673. https://doi.org/doi.org/10.3390/cells11172673. | |
dc.identifier.issn | 2073-4409 | es |
dc.identifier.uri | https://hdl.handle.net/11441/144757 | |
dc.description.abstract | Background: Sorafenib constitutes a suitable treatment alternative for patients with advanced hepatocellular carcinoma (HCC) in whom atezolizumab + bevacizumab therapy is contraindicated. The aim of the study was the identification of a miRNA signature in liquid biopsy related to sorafenib response. Methods: miRNAs were profiled in hepatoblastoma HepG2 cells and tested in animal models, extracellular vesicles (EVs), and plasma from HCC patients. Results: Sorafenib altered the expression of 11 miRNAs in HepG2 cells. miR-200c-3p and miR-27a-3p exerted an anti-tumoral activity by decreasing cell migration and invasion, whereas miR-122-5p, miR-148b-3p, miR-194-5p, miR-222-5p, and miR-512-3p exerted pro-tumoral properties by increasing cell proliferation, migration, or invasion, or decreasing apoptosis. Sorafenib induced a change in EVs population with an increased number of larger EVs, and promoted an accumulation of miR-27a-3p, miR-122-5p, miR-148b-3p, miR-193b-3p, miR-194-5p, miR-200c-3p, and miR-375 into exosomes. In HCC patients, circulating miR-200c-3p baseline levels were associated with increased survival, whereas high levels of miR-222-5p and miR-512-3p after 1 month of sorafenib treatment were related to poor prognosis. The RNA sequencing revealed that miR-200c-3p was related to the regulation of cell growth and death, whereas miR-222-5p and miR-512-3p were related to metabolic control. Conclusions: The study showed that Sorafenib regulates a specific miRNA signature in which miR-200c-3p, miR-222-5p, and miR-512-3p bear prognostic value and contribute to treatment response. | es |
dc.format | application/pdf | es |
dc.format.extent | 24 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Cells, 11 (17), 2673. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | extracellular vesicle | es |
dc.subject | hepatocellular carcinoma | es |
dc.subject | miRNA | es |
dc.subject | liquid biopsy | es |
dc.subject | Sorafenib | es |
dc.title | miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Fisiología Médica y Biofísica | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Cirugía | es |
dc.relation.projectID | PI16/00090 | es |
dc.relation.projectID | PI19/01266 | es |
dc.relation.projectID | PI-0198-2016 | es |
dc.relation.projectID | FPU17/00026 | es |
dc.relation.projectID | EST19/01091 | es |
dc.relation.projectID | PI15/00145 | es |
dc.relation.projectID | PI18/0358 | es |
dc.relation.projectID | PI18/00768 | es |
dc.relation.projectID | PI044031 | es |
dc.relation.publisherversion | mdpi.com/2073-4409/11/17/2673 | es |
dc.identifier.doi | doi.org/10.3390/cells11172673 | es |
dc.journaltitle | Cells | es |
dc.publication.volumen | 11 | es |
dc.publication.issue | 17 | es |
dc.publication.initialPage | 2673 | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | Consejería de Igualdad, Salud y Políticas Sociales | es |
dc.contributor.funder | Ministerio de Educación, Cultura y Deporte | es |
dc.contributor.funder | FPU estancias breves 2019 | es |
dc.contributor.funder | GEIVEX Mobility Fellowships 2020 | es |
dc.contributor.funder | European Development Regional Fund "A way to achieve Europe" ERDF | es |
dc.contributor.funder | Asociación Española Contra el Cáncer | es |